Search Results for: search.html/whatis/diagnosis.html/page/polyangiitis.html/treatments/prednisone.html

• First Description
• Who gets Takayasu’s Arteritis (the “typical” patients)?
• Classic symptoms of Takayasu’s Arteritis
• What causes Takayasu’s Arteritis?
• How is Takayasu’s Arteritis diagnosed?
• Treatment and Course of Takayasu’s Arteritis
• What’s new in Takayasu’s Arteritis?
• In medical terms, by David Hellmann, M.D.

First Description

The first case of Takayasu’s arteritis was described in 1908 by Dr. Mikito Takayasu at the Annual Meeting of the Japan Ophthalmology Society. Dr. Takayasu described a peculiar “wreathlike” appearance of blood vessels in the back of the eye (retina). Two Japanese colleagues at the same meeting reported similar eye findings in patients whose wrist pulses were absent. It is now known that the blood vessel malformations that occur in the retina are a response (new blood vessel growth) to arterial narrowings in the neck, and that the absence of pulses noted in some patients occur because of narrowings of blood vessels to the arms. The eye findings described by Dr. Takayasu are rarely seen in patients from North America.

Pictured below is a close–up view of an angiogram of the left vertebral and subclavian arteries in a patient with Takayasu’s arteritis. Note the narrowing and irregularities that occur at several sites, and the “corkscrew” configuration of one vessel segment near the junction of the two arteries. These changes, caused by inflammation in the blood vessel wall, sometimes cause complete blockage of the artery.

Takayasu’s arteritis is occasionally called “pulseless disease”, because of the difficulty in detecting peripheral pulses that sometimes occurs as a result of the vascular narrowings.

Who gets Takayasu’s Arteritis?

The “typical” patient with Takayasu’s arteritis is a woman under the age of 40. There is a 9:1 female predominance in this disease. Although the disease has a worldwide distribution, it appears to occur more often in Asian women.

Takayasu’s arteritis is a rare disease. The best estimates of the disease frequency suggest that 2 or 3 cases occur each year per million people in a population.

Classic Symptoms of Takayasu’s Arteritis

Takayasu’s arteritis is a chronic inflammatory condition that affects the largest blood vessel in the body (the aorta) and its branches. Thus, the complications of Takayasu’s arise directly or indirectly from damage to these blood vessels. The vasculitides are classified according to the size of blood vessel involved. Takayasu’s is the classic “large vessel” vasculitis.

Pictured below is a normal aortic arch on the left, with narrow, smooth blood vessels. On the right is an example of an abnormal aortic arch in a patient with Takayasu’s, with obvious dilation of the ascending aorta on the left side of the picture.

Clinicians divide Takayasu’s arteritis into two phases: 1) a systemic phase; and 2) an occlusive phase. Although these two phases are not always distinct (i.e., patients may have features of both phases at the same time), this division is a useful way of thinking about the disease.

In the systemic phase, patients have symptoms and signs of an active inflammatory illness. These may include “constitutional symptoms” (fever, fatigue, weight loss), arthritis, and non-specific aches and pains. There may be tenderness overlying affected arteries. Most patients have elevations of the erythrocyte sedimentation rate during the systemic phase.

The systemic phase is succeeded by the occlusive phase, during which patients begin to develop symptoms caused by the narrowing of affected arteries. These may include pain in the limbs that occurs during repetitive activities (“claudication”), such as pain in the arm that occurs while using a handsaw or pain in the calves brought on by walking. The symptoms also include dizziness upon standing up, headaches, and visual problems. During the occlusive phase, affected blood vessels may be narrowed to such an extent that the normal arterial pulsations (“pulses”) in the neck, elbow, wrist, or lower extremities cannot be felt. Using a stethoscope, one may also hear “bruits” (pronounced ‘brew eez’), a harsh, “whooshing” sounds made by the flow of blood through abnormally narrowed vessels. High blood pressure is common, but blood pressures taken in the arms may be read as falsely low if there is a narrowing of an artery high up in the arm. With some patients, it is not possible to get accurate blood pressure readings in the arms. Using an ophthalmoscope, a physician may observe characteristic malformations of blood vessels that occur in advanced cases of Takayasu’s arteritis.

Although the lung involvement in Takayasu’s is frequently overshadowed by involvement of systemic large blood vessels, the pulmonary arteries may also be affected in this disorder. Pictured below is a pulmonary angiogram demonstrating beading and cut–off lesions of the right pulmonary arteries, and a large aneurysm of the left pulmonary artery.

What Causes Takayasu’s Arteritis?

The cause of Takayasu’s arteritis is not known. Some evidence suggests that an infection of some kind — viral, bacterial, or other — occurring in a person with other predisposing factors (such as the correct genes), may lead to this disease. This is an attractive hypothesis, but definitive evidence for it is lacking.

How is Takayasu’s Arteritis Diagnosed?

Making the diagnosis of Takayasu’s arteritis can be extremely difficult. Unfortunately it is very common for the disease to smoulder in the walls of large blood vessels for years, causing only non-specific symptoms associated with the systemic phase of the illness (or no symptoms), until a major complication results. These major complications may include dilation of the aorta with “stretching” of the aortic valve in the heart; critically reduced blood flow to an arm or leg; a stroke caused by high blood pressure in vessels of the brain, and many others.

Once the diagnosis is suspected, it is usually confirmed by a radiographic procedure such as an angiogram or a magnetic resonance imaging study demonstrating significant large artery disease consistent with Takayasu’s. In some cases in which blood vessel damage is so severe as to necessitate surgery to repair the aortic valve, the aorta, or some other large blood vessel, physicians are able to make unequivocal diagnoses by looking at tissue from the involved blood vessels under the microscope. Takayasu’s arteritis is pathologically indistinguishable from giant cell arteritis. In both, destruction of the blood vessel wall and giant cells are frequently present.

Pictured below is an example of large artery involvement in Takayasu’s arteritis. Magnetic resonance imaging study of the aorta and large blood vessels of the upper extremities, showing a large aneurysm of the ascending aorta, blockage of the right axillary artery (note the interruption of blood flow near the shoulder on the left of the figure), and many narrowings of the left subclavian artery (on the right of the figure).

Treatment and Course of Takayasu’s Arteritis

The great majority of patients with Takayasu’s arteritis respond to prednisone. The usual starting dose is approximately 1 milligram per kilogram of body weight per day (for most people, this is approximately 60 milligrams a day). Because of the significant side–effects of long-term high–dose prednisone use, the starting dose is tapered over several weeks to a dose that the physician feels is tolerable for the patient.

For long–term treatment in addition to prednisone (as “steroid sparing agents”), methotrexate, azathioprine, and even cyclophosphamide are sometimes used. There have been few studies of the use of these medications in this disease.

What’s New in Takayasu’s Arteritis?

One of the biggest problems confronting Takayasu’s patients and the physicians who care for them is determining how active the disease is. This can be an exceptionally challenging problem. The erythrocyte sedimentation rate (ESR) probably remains the most reliable marker of disease activity, but even this test is not helpful in a sizeable number of patients who have active arterial inflammation but normal ESRs. Because the treatments for Takayasu’s arteritis may be associated with substantial side–effects, we need more accurate means of gauging disease activity.

To this end, a study conducted by the International Network for the Study of Systemic Vasculitides (“INSSYS”) may be helpful. Investigators from INSSYS, which includes more than 300 physicians, scientists, and other experts in vasculitis from more than 50 different medical centers across the world, have been conducting a “Surrogate Markers Study” for the past several years. In this study, the investigators examine blood specimens from patients with vasculitis for the purpose of identifying proteins and other molecules whose presence indicates ongoing inflammation. Improved understanding of these diseases at a molecular level may permit more rational use of treatments in the future.

In medical terms, by David Hellmann, M.D.

A discussion of Takayasu’s Arteritis written in medical terms by David Hellmannn, M.D. (F.A.C.P.), The Johns Hopkins Vasculitis Center, for the Rheumatology Section of the Medical Knowledge Self-Assessment Program published and copyrighted by the American College of Physicians (Edition 11, 1998). The American College of Physicians has given us permission to make this information available to patients contacting our Website.

Takayasu’s arteritis is a granulomatous vasculitis chiefly of young women that involves the aorta and its major branches. Patients can present initially with obscure systemic symptoms such as fever of unknown origin or more commonly with symptoms and signs of large vessel vasculitis such as hypertension from renal artery stenosis, aortic regurgitation from aortitis, or stroke from carotid artery occlusion. Bruits and diminished or absent pulses are the most reliable signs. Anemia and elevated ESR accompany active disease. Diagnosis is confirmed by angiography showing stenosis and dilation of the aorta, its branches, or both. Thickening of the aortic wall detectable by MRI or ultrasonography can precede angiographic changes. Prednisone is effective for the systemic symptoms and can thwart progression of the vasculitis. Methotrexate may be an effective corticosteroid-sparing agent. Angioplasty alleviates renal artery stenosis about half the time. When needed, vascular bypass procedures and aortic valve replacement usually work well if deferred until the disease is inactive. Estimating disease activity is difficult but is based on systemic symptoms, anemia, ESR, progression of lesions, and pathology (when available).

• What causes vasculitis?
• What is going to happen to me?
• Is vasculitis curable?
• Is vasculitis hereditary?
• Does diet affect vasculitis?
• Will my vasculitis return?
• How should I guard against the occurrence of a disease flare?
• Why do I have to have bloodwork checked frequently?

What causes vasculitis?

The causes of most forms of vasculitis remain unknown. Infections are strongly suspected of playing a role in in forms such as the association of hepatitis B (a virus) and polyarteritis nodosa, and hepatitis C (another virus) and cryoglobulinemic vasculitis. Bacterial infections have been suspected of playing a possible role in granulomatosis with polyangiitis (GPA, formerly known as Wegener’s) which is the reason that some patients with GPA that is limited to the upper respiratory tract are treated only with an antibiotic, Bactrim (trimethoprim/sulfamethoxazole). A general theory that applies to many types of vasculitis is that the disease results from the occurrence of a particular infection in a person whose genes (and other factors) make him/her susceptible to developing vasculitis.

What is going to happen to me?

The course of vasculitis is often difficult to predict. Some types of vasculitis may occur only once and do not return. Other types are prone to recurrences. For all patients with vasculitis, it is essential to be evaluated by physicians who are experienced in the treatment of these diseases. Vasculitis is treatable, and many patients achieve remissions through treatment. It is important to balance the types of medications necessary to control the disease and the risk of side effects that those medicines often bring. A primary aim of several ongoing new studies in vasculitis is to find drugs that help maintain remission.

Is vasculitis curable?

Most forms of vasculitis are treatable if detected early enough, before substantial organ damage has occurred. While often effective, however, the treatments remain imperfect and require improvement. Further research is needed in all forms of vasculitis. Greater knowledge of these diseases will lead to better treatments and, some day, to cures.

Will my children or other family members get it?

Vasculitis is not contagious. One cannot acquire vasculitis from contact with a vasculitis patient. In addition, despite the fact that genes probably play a role in susceptibility to some forms of vasculitis, it is unusual for vasculitis to occur in more than one member of the same family. Thus, vasculitis is not a heritable disorder. All of these points illustrate the fact that the causes of vasculitis are complex. In all likelihood, patients develop vasculitis because of the simultaneous occurrence of multiple risk factors, most of which remain poorly understood.

Does diet affect vasculitis?

This is one of the most commonly-asked questions by patients with vasculitis. All patients want to do whatever is within their power to help treat their disease. Unfortunately, there is presently no evidence that a person’s diet affects susceptibility to vasculitis, or that consuming or avoiding certain foods or beverages affects the course of the disease. In general, we advocate eating a balanced healthy diet rich in protein and vegetables. Avoidance of excessive empty calories, processed foods, and sugars may be very important, particularly in patients on steroids who are at risk for weight gain.

Will my vasculitis return?

After patients achieve remission from their vasculitis, it is logical for them to wonder if their disease will ever return. The answer, which is often difficult to give with certainty, depends in large part on the patient’s specific type of vasculitis. For example, some types of vasculitis, such as Henoch-Schönlein purpura (HSP) or vasculitis caused by a medication, are often self-limited and resolve on their own. Other forms of vasculitis (e.g., Buerger’s disease, a disease strongly associated with cigarette smoking) resolve with institution of the definitive treatment: smoking cessation.

However,  other forms of vasculitis behave less predictably and never come back in some patients but recur frequently in others. Granulomatosis with polyangiitis (GPA), giant cell arteritis (GCA), Takayasu arteritis, microscopic polyangiitis, and many other types of vasculitis fall into the category of diseases that have periods of quiescence and periods of flare. Disease flares in vasculitis can be mild (rash, minor joint pains) or severe (renal failure, skin ulcers). Flares may occur if medications are discontinued or dosage is lowered. Flare may occur in the context of infection. Often the reason for disease flare is unknown.

At the present time, the ability of doctors to predict who will suffer disease flares and who will maintain in long-term remissions (or be cured) needs refinement. Progress in this area will come through research.

How should I guard against the occurrence of a disease flare?

We believe that several points are worth keeping in mind:

First, the symptoms of flares are usually very similar those experienced at the onset of disease. If headaches signaled the beginning of giant cell arteritis, then the recurrence of headaches may indicate a disease flare. If leg ulcers began as painful red lumps on the leg the first time, then the return of painful red lumps may mean that vasculitis is back. Patients must become experts about their own manifestations of vasculitis so that they can recognize them immediately, consult their doctors, and begin appropriate treatment before serious damage occurs.

Second, we believe that patients truly know and understand their own bodies. It is important to discuss new or changing symptoms with your physicians. Together, patients and physicians can determine if new symptoms truly represent a vasculitis flare or if the cause is something equally as likely (medication side effect, infection, or other common medical issues).

Finally, because vasculitis treatments require careful monitoring by doctors, patients should discuss any changes in treatment with their physicians. Increasing or decreasing medications without consulting a physician may lead to trouble.

Why do I have to have bloodwork checked frequently?

Blood tests are helpful to monitor for the return of vasculitis by keeping a watchful eye on important parameters such as kidney function, liver tests, and markers of inflammation (ESR and CRP). Blood tests are also very important to ensure that medications are not causing any side effects such as liver irritation or low blood counts.

How often should my blood be checked?

This depends on the specific medicine or medicines that you take. Patients on cyclophosphamide (Cytoxan) should have their counts checked every week. Patients on most other kinds of medications used to treat vasculitis (Methotrexate, Azathioprine) usually only need to have their blood work checked monthly. If some laboratory tests are abnormal or nearly so, then more frequent monitoring may be required.

What type of tests do we check?

Regardless of the type of vasculitis and the exact type of medication that a patient takes, similar types of tests are monitored. These tests are:

1. a complete blood count;
2. tests of kidney function including a urinalysis; and
3. liver function tests.

The table below outlines the importance behind checking each of these tests.

Type of Test	What should be checked	Why?
Complete Blood Count (“CBC”)	White blood cells (WBC) Platelets Hematocrit	Low WBC count may lead to infections. Low platelets may cause bleeding. Low hematocrit means insufficient oxygen-carrying capacity of the blood.
Kidney Function	Creatinine Blood Urea Nitrogen (BUN)	High creatinine and BUN indicate that the kidneys are not performing their blood-cleansing function properly.
Urinalysis	Protein Level Red Blood Cells	Normal urinalyses have no protein and no blood. The presence of protein and/or blood in the urine may indicate active vasculitis in the kidneys (or damage to the bladder from cyclophosphamide).
Liver Function	Albumin Aspartate aminotransferase(AST) Alanine aminotransferase (ALT)	Often a good indication of overall health. Elevated AST/ALT levels indicate inflammation in the liver (usually caused by medications).

• First Description
• Who gets Behcet’s Disease (the “typical” patients)?
• Classic symptoms of Behcet’s Disease
• What causes Behcet’s Disease?
• How is Behcet’s Disease diagnosed?
• Treatment and Course of Behcet’s Disease
• What’s new in Behcet’s Disease?

First Description

In the 1930’s, a Turkish dermatologist, Hulusi Behcet, noted the triad of aphthous oral ulcers, genital lesions, and recurrent eye inflammation, and became the first physician to describe the disease in modern times. Another name for Behcet’s Disease is Behcet’s syndrome.

Who gets Behcet’s Disease (the “typical” patient)?

Behcet’s disease is most common along the “Old Silk Route,” which spans the region from Japan and China in the Far East to the Mediterranean Sea, including countries such as Turkey and Iran. Although the disease is rare in the United States, sporadic cases do occur in patients who would not appear to be at risk because of their ethnic backgrounds (e.g., in Caucasians or African–Americans). The disease is not rare in regions along the Old Silk Route, but the disease’s epidemiology is not well understood. In Japan, Behcet’s disease ranks as a leading cause of blindness. Below is a magnetic resonance image (MRI) study of a Behcet’s patient demonstrating central nervous system involvement (white matter changes in the pons).

Classic symptoms and signs of Behcet’s Disease

Behcet’s disease is virtually unparalleled among the vasculitides in its ability to involve blood vessels of nearly all sizes and types, ranging from small arteries to large ones, and involving veins too. Because of the diversity of blood vessels it affects, manifestations of Behcet’s may occur at many sites throughout the body. However, the disease has a predilection for certain organs and tissues; these are described below.

• Eye
• Mouth
• Skin
• Lungs
• Joints
• Brain
• Genitals
• Gastrointestinal Tract

Eye

• Behcet’s may cause either anterior uveitis (inflammation in the front of the eye) or posterior uveitis (inflammation in the back of the eye), and sometimes causes both at the same time.
• Anterior uveitis results in pain, blurry vision, light sensitivity, tearing, or redness of the eye.
• Posterior uveitis may be more dangerous and vision–threatening because it often causes fewer symptoms while damaging a crucial part of the eye — the retina.

(top of section)

Mouth

• Painful sores in the mouth called “aphthous ulcers”(pictured below). These are very similar in appearance to ulcers that frequently occur in the general population, usually as a result of minor trauma. In Behcet’s, however, the lesions are more numerous, more frequent, and often larger and more painful. Aphthous ulcers can be found on the lips, tongue, and inside of the cheek. Aphthous ulcers may occur singly or in clusters, but occur in virtually all patients with Behcet’s.

Skin

• Pustular skin lesions that resemble acne, but can occur nearly anywhere on the body. This rash is sometimes called “folliculitis”.
• Skin lesions called erythema nodosum: red, tender nodules that usually occur on the legs and ankles but also appear sometimes on the face, neck, or arms. Unlike erythema nodosum associated with other diseases (which heal without scars), the lesions of Behcet’s disease frequently ulcerate.

Lungs

• Aneurysms (outpouchings of blood vessel walls, caused by inflammation) of arteries in the lung, rupture of which may lead to massive lung hemorrhage.

Joints

• Arthritis or “arthralgias” (pain in the joints not accompanied by joint swelling).

Brain

• Central nervous system involvement is one of the most dangerous manifestations of Behcet’s. The disease tends to involve the “white matter” portion of the brain and brainstem, and may lead to headaches, confusion, strokes, personality changes, and (rarely) dementia. Behcet’s may also involve the protective layers around the brain (the meninges), leading to meningitis. Because the meningitis of Behcet’s disease is not associated with any known infection, it is often referred to as “aseptic” meningitis.

Genitals

• Male — painful genital lesions that form on the scrotum, similar to oral lesions, but deeper.
• Female — painful genital ulcers that develop on the vulva.

Gastrointestinal

• Ulcerations may occur anywhere in the gastrointestinal tract from the mouth to the anus. The terminal ileum and cecum are common sites. Involvement of the GI tract by Behcet’s may be difficult to distinguish from inflammatory bowel disease (such as Crohn’s disease).

Blood Vessels

• Clots can occur in veins in any site, most often including veins in the lower extremity (superficial or deep venous thrombosis).
• Inflammation in arteries can occur as well, such as the pulmonary or abdominal arteries, sometimes causing obstruction of the vessel (thrombosis).

What causes Behcet’s Disease?

Behcet’s is one of the few forms of vasculitis in which there is a known genetic predisposition. The presence of the gene HLA–B51 is a risk factor for this disease. However, it must be emphasized that presence of the gene in and of itself is not enough to cause Behcet’s: many people possess the gene, but relatively few develop Behcet’s. Despite the predisposition to Behcet’s conferred by HLA–B51, familial cases are not the rule, constituting only about 5% of cases. Thus, it is believed that other factors (perhaps more than one) play a role. Possibilities include infections and other environmental exposures.

How is Behcet’s Disease Diagnosed?

There is not one specific test to diagnose Behcet’s. Rather the diagnosis is based on the occurrence of symptoms and signs that are compatible with the disease. The presence of certain features that are particularly characteristic (e.g., oral or genital ulcerations), elimination of other possible causes of the patient’s symptoms, and if possible, proof of vasculitis by biopsy of an involved organ would together support a diagnosis of Behcet’s.

A positive pathergy test can be supportive of the diagnosis of Behcet’s but is not diagnostic by itself of the condition. A pathergy test is a simple test in which the forearm is pricked with a small, sterile needle. Occurrence of a small red bump or pustule at the site of needle insertion constitutes a positive test. Please note, that although a positive pathergy test is helpful in the diagnosis of Behcet’s, only a minority of Behcet’s patients demonstrate the pathergy phenomenon (i.e., have positive tests). Patients from the Mediterranean region are more likely to demonstrate pathergy. In addition, other conditions can occasionally result in positive pathergy tests, so the test is not 100% specific.

Pictured below is an example of the pathergy test; 1) taken at the time when the patient was “stuck” with the sterile needle; 2) shows the area immediately after the stick; 3) & 4) show the area one day and two days after the needle stick, respectively.

Treatment and Course of Behcet’s Disease

For disease that is confined to mucocutaneous regions (mouth, genitals, and skin), topical steroids and non–immunosuppressive medications such as colchicine or dapsone may be effective. Apremilast (Otezla) is now FDA-approved for treatment of oral ulcers in Behcet’s. Moderate doses of systemic corticosteroids are also frequently required for disease exacerbations. Some patients require chronic, low doses of prednisone or conventional immunosuppressives such as (azathioprine) to keep the disease under control.

In the event of serious end–organ involvement such as eye or central nervous system disease, both high doses of prednisone and some other form of immunosuppressive treatment are usually necessary. Immunosuppressive agents used in the treatment of Behcet’s include azathioprine, cyclosporine, cyclophosphamide, and TNF-alpha inhibitors (infliximab, adalimumuab). Cyclophosphamide is generally used in life-threatening disease, such as central nervous system involvement. Blood clots can be another manifestation of Behcet’s, and in some scenarios blood thinners may be used in treatment.

 

The term “vasculitis” refers to a group of inflammatory diseases that cause inflammation centered in the wall of blood vessels. This vascular inflammation ultimately leads to damage and dysfunction of the organs that contain the affected vessels. The symptoms of vasculitis depend on the particular blood vessels (and organs) that are involved by the inflammatory process.

As a group, the vasculitis syndromes have the ability to affect nearly every organ in the body. Yet different forms of vasculitis tend to involve blood vessels in specific locations throughout the body. For example, Giant Cell Arteritis typically involves the medium– to large–sized blood vessels supplying the head and neck, but rarely involves the blood vessels of the kidneys. In contrast, Granulomatosis with Polyangiitis (GPA) frequently involves the kidneys, very often the lungs, and almost always the upper respiratory tract, but rarely blood vessels to the brain.

Different types of vasculitis have characteristic (localized) patterns of blood vessel involvement.  However, vasculitis is often a systemic illness. Thus, patients with vasculitis generally feel sick. They often have fevers, weight loss, fatigue, a rapid pulse, and diffuse aches and pains that are difficult to pinpoint. It has been said that vasculitis is a “hurting disease”, because it is so commonly associated with pain of one type or another: pain from a nerve infarction, pain from insufficient blood to the gastrointestinal tract, pain from skin ulcers. In some cases, however, identifying the source and underlying cause of the pain is extremely challenging. Because vasculitis can involve virtually every organ system in the body, it often masquerades as other diseases, and may be a challenging diagnosis to make.

What organ systems may be affected?

It is important to note that not every organ system will be affected in every patient. The pattern of organ involvement (and symptoms) is unique to the individual, as well as the type of vasculitis (category).

Skin

A variety of rashes, the most classic of which is “palpable purpura” –purplish–red spots, usually found on the legs. These spots can usually be felt by the examiner’s fingertips, hence the descriptor “palpable”.

Joints

Symptoms range from full–blown arthritis to aches in the joints without obvious swelling (arthralgias).

Lungs

Cough (particularly coughing up blood), shortness of breath, a pneumonia–like appearance to a patient’s chest X–ray, lung “infiltrates”, and the development of cavities in the lungs are among the manifestations that may occur in forms of vasculitis with lung involvement.

Kidneys

In contrast to many other organs, inflammation in the kidneys does not hurt or cause other symptoms a patient would notice until renal damage is quite advanced. Instead, evidence of vasculitis involving the kidneys is made by obtaining lab tests, and in many cases a kidney biopsy. Glomerulonephritis is the most common type of kidney damage encountered in vasculitis. This syndrome can cause abnormal lab findings in the urine, including the presence of red blood cells (usually invisible to the naked eye), clumps of red blood cells (known as “casts”, also invisible to the naked eye), and abnormal levels of protein in the urine. If renal involvement is not recognized, renal failure can develop, sometimes leading to the need for dialysis or kidney transplant.

Blood

Vasculitis can cause abnormal findings on blood counts. Anemia (low hematocrit or red blood cell count) is a typical finding in patients with active vasculitis. A slightly elevated white blood cell count may also occur. These findings are very non-specific, meaning that they can occur in many other situations and diseases. Elevated inflammatory markers (erythrocyte sedimentation rate and C-reactive protein) are also frequently identified in patients with active vasculitis.

Sinus, Nose & Ears

The sinuses, nose and ears are common sites of involvement by ANCA-associated vasculitis, including GPA, EGPA and MPA. Symptoms can include chronic sinus congestion and “infections” that persist for longer than they should and require repeated courses of antibiotics; bleeding from the nose; perforations (holes) in the nasal septum; hearing loss; inflammatory fluid in the ears requiring drainage; inflammation in the cartilage of the ears or nose.

Eyes

Brain

Nerve

Peripheral nerves are a relatively common site of vasculitis involvement. Damage to the peripheral nerves can cause shooting pains in the arms and legs, numbness, and asymmetrical weakness (i.e., weakness that involves one side of the body more than the other).

All information contained within the Johns Hopkins Vasculitis Center website is intended for educational purposes only. Visitors are encouraged to consult other sources and confirm the information contained within this site. Consumers should never disregard medical advice or delay in seeking it because of something they may have read on this website.